A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL: Intismeran autogene
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]